Is the world ready for gene therapy?

Area of Science:

• * Health Economics and Outcomes Research
• * Rare Disease Therapeutics
• * Gene Therapy Policy

Background:

• * Gene therapies represent a significant advancement in treating rare diseases like hemophilia.
• * Current healthcare frameworks may not adequately address the unique challenges of evaluating and valuing these innovative treatments.
• * The introduction of gene therapies necessitates an evolution in healthcare system preparedness.

Purpose of the Study:

• * To assess the state-of-the-art requirements and challenges for gene therapy evaluation and valuation in hemophilia care.
• * To identify key considerations for healthcare systems, payers, and health technology assessment (HTA) authorities.
• * To propose strategies for ensuring broad access to gene therapies for individuals with hemophilia.

Main Methods:

• * Comprehensive review of current literature and expert perspectives on gene therapy in hemophilia.
• * Analysis of evaluation and valuation methodologies for rare disease treatments.
• * Discussion of stakeholder collaboration and policy implications.

Main Results:

• * Patient-defined value frameworks are essential for capturing multi-dimensional, patient-centered outcomes.
• * Alternative payment models and risk-sharing arrangements are needed to address uncertainties in clinical and economic value.
• * HTA authorities require flexibility in evidence requirements due to the nature of rare disease data and long-term uncertainties.

Conclusions:

• * Evolving healthcare frameworks is critical for the successful integration of gene therapies in hemophilia care.
• * Collaboration among stakeholders is paramount for developing evidence requirements and incentives.
• * Sustainable budgets and broad patient access worldwide depend on adaptive evaluation and valuation strategies.